Home

Atlas of Colposcopy: Principles and Practice

Filter by language: English / 中文 / Français / Español / Português / Русский

Early and advanced cancers / Squamous cell cancer
Go back to the list    

  

  • Age: 52
  • HPV status: Positive


  • After normal saline

    After acetic acid

    After acetic acid with green filter

    After acetic acid with green filter

    After Lugol’s iodine

    Colposcopy report (2011 IFCPC nomenclature):
    / Post-treatment consequence / Endometriosis

    General assessment
  • Adequacy:
  • Squamocolumnar junction visibility:
  • Transformation zone:

  • Normal colposcopic findings
  • Original squamous epithelium:
  • Columnar epithelium:
  • Metaplastic squamous epithelium:
  • Deciduosis in pregnancy:

  • Abnormal colposcopic findings
    General principles
    Position and size
  • Location of the lesion:
  • Location of the lesion by clock position:
  • No. of quadrants:
  • % of cervix:

  • Grade 1 (minor)

    Grade 2 (major)

    Non-specific

    Suspicious for invasion

    Miscellaneous finding



    Swede score:

    Swede score
    0
    1
    2
    Aceto uptake
    Nil or transparentThin, milkyDistinct, stearin
    Margins
    Nil or diffuseSharp but irregular, jagged, satellitesSharp and even, difference in level
    Vessels
    Fine, regularAbsentCoarse or atypical vessels
    Lesion size
    < 5 mm5-15 mm or 2 quadrants>15 mm, 3-4 quadrants, or endocervically undefined
    Iodine uptake
    BrownFaintly or patchy yellowDistinctly yellow

    Final Swede score: 10



    Case Summary
    Provisional diagnosis: Type 3 transformation zone; suspicion of early invasive squamous cell carcinoma.
     
    Management: Multiple punch biopsies from the posterior lip of the cervix.
     
    Histopathology: Invasive squamous cell carcinoma.
     
    Comment: Because the lesion is predominantly in the endocervical canal, punch biopsy can often be unreliable. A diagnostic excision by LLETZ or cold-knife conization is more efficient in determining the severity of the disease.


      
    25 avenue Tony Garnier CS 90627 69366, LYON CEDEX 07 France - Tel: +33 (0)4 72 73 84 85
    © IARC 2024 - Terms of use  -  Privacy Policy.